Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Stones

Tolvaptan might prevent kidney stone formation

Subjects

Tolvaptan, an arginine vasopressin receptor antagonist, decreases urinary supersaturation in kidney stone formers by considerably increasing diuresis, suggesting that this drug might be an effective therapy for reducing the risk of developing kidney stones in these patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cheungpasitporn, W., Erickson, S. B., Rule, A. D., Enders, F. & Lieske, J. C. Short term tolvaptan increases water intake and effectively decreases urinary calcium oxalate, calcium phosphate, and uric acid supersaturations. J. Urol. http://dx.doi.org/10.1016/j.juro.2015.11.027 (2015).

  2. Borghi, L. et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J. Urol. 3, 839–843 (1996).

    Google Scholar 

  3. de Boer, H., Roelofsen, A. & Janssens, P. M. Antidiuretic hormone antagonist to reduce cystine stone formation. Ann. Intern. Med. 6, 459–460 (2012).

    Article  Google Scholar 

  4. Watkins, P. B. et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 11, 1103–1113 (2015).

    Article  Google Scholar 

  5. Hanouna, G., Haymann, J. P., Baud, L. & Letavernier, E. Vasopressin regulates renal calcium excretion in humans. Physiol. Rep. 3, e12562 (2015).

    Article  Google Scholar 

  6. Decaux, G., Van Laethem, Y., Van Kuyck, M. & Mockel, J. Hypercalciuria in the syndrome of inappropriate secretion of antidiuretic hormone. Miner. Electrolyte Metab. 4, 192–196 (1982).

    Google Scholar 

  7. Chang, Y. L., Lin, A. T. & Chen, K. K. Short-term effects of desmopressin on water and electrolyte excretion in adults with nocturnal polyuria. J. Urol. 6, 2227–2229 (2007).

    Article  Google Scholar 

  8. Tamma, R. et al. Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proc. Natl Acad. Sci. USA 46, 18644–18649 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Emmanuel Letavernier or Michel Daudon.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Letavernier, E., Daudon, M. Tolvaptan might prevent kidney stone formation. Nat Rev Urol 13, 130–131 (2016). https://doi.org/10.1038/nrurol.2016.11

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2016.11

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing